Abstract
Introduction
Tracheoesophageal speech is considered the gold standard for rehabilitation following total laryngectomy. Current literature is limited and contradictory about the possible causes of device failure. The aim of the study is to compare the device life-time between the Provox 2 and Provox Vega and to examine possible related factors that influence their duration.
Methods
Retrospective case-crossover study in 34 laryngectomized patients who had undergone tracheoesophageal voice rehabilitation using indwelling Provox 2 and Provox Vega voice prostheses between 2010 and 2016 in a tertiary care centre.
Results
A total of 440 prostheses were evaluated. The most frequent reason for replacement was due to an endoprosthesis leakage (n = 221, 64.2%) in both models. Radiotherapy increases the risk of prosthesis replacement (IRR = 1.88, p = 0.007) as well as bilateral neck dissection (IRR = 1.56, p = 0.017) in Provox 2. Age and unilateral neck dissection do not seem to influence the duration of the prosthesis. Mean life-time of Provox 2 was 106.64 days and 124.19 days for Provox Vega (p = 0.261). Complementary treatment with radiotherapy demonstrated a lower device survival (p < 0.001).
Discussion
Results confirmed the non-significant differences on device life between Provox Vega and Provox 2, as well as the relevant role of radiotherapy treatment in the increase of replacements and diminution of the device duration.
Similar content being viewed by others
References
Pawar PV, Sayed SI, Kazi R, Jagade MV (2008) Current status and future prospects in prosthetic voice rehabilitation following laryngectomy. J Cancer Res Ther 4(4):186–191
El Sistema Provox [Internet]. Atos Medical [cited February, 2018]. https://www.atosmedical.es/other-areas-2/protesis-de-titanio-para-el-oido-medio/vivir-con-una-laringectomia/el-sistema-provox/
Blom-Singer Voice Prosthesis [Internet]. [cited February, 2018]. https://www.atosmedical.es/other-areas-2/protesis-de-titanio-para-el-oido-medio/vivir-con-una-: http://www.inhealth.com/category_s/44.htm
Nijdam HF, Annyas AA, Laan KT van der, Schutte HK (1986) The Groningen voice prosthesis for voice rehabilitation during total laryngectomy. Speech restoration via voice prostheses. Springer, Berlin, pp 23–25
Kress P, Schäfer P, Schwerdtfeger FP, Rösler S (2014) Are modern voice prostheses better? A lifetime comparison of 749 voice prostheses. Eur Arch Otorhinolaryngol 271(1):133–140
Graville DJ, Palmer AD, Andersen PE, Cohen JI (2011) Determining the efficacy and cost-effectiveness of the activalve: results of a long-term prospective trial. Laryngoscope 121(4):769–776
Schuldt T, Ovari A, Dommerich S (2013) The costs for different voice prostheses depending on the lifetime. Laryngorhinootologie 92(6):389–393
Lorenz KJ (2015) The development and treatment of periprosthetic leakage after prosthetic voice restoration. A literature review and personal experience part I: the development of periprosthetic leakage. Eur Arch Otorhinolaryngol 272(3):641–659
Lewin JS, Baumgart LM, Barrow MP, Hutcheson KA (2017) Device life of the tracheoesophageal voice prosthesis revisited. JAMA Otolaryngol Head Neck Surg 143(1):65–71
González Poggioli N, Herranz González-Botas J, Vázquez Barro JC, Novoa Juiz V, Martínez Vidal J (2007) Fístulas fonatorias hoy. Acta Otorrinolaringol Esp 58(3):110–112
Thylur DS, Villegas BC, Fisher LM, Sinha UK, Kokot N (2016) Device life of two generations of provox voice prostheses. Ann Otol Rhinol Laryngol 125(6):501–507
Hancock KL, Lawson NR, Ward EC (2013) Device life of the Provox Vega voice prosthesis. Eur Arch Otorhinolaryngol 270(4):1447–1453
Fusconi M, Taddei AR, Gallo A, Conte M, De Virgilio A, Greco A et al (2014) Degradation of silicone rubber causes Provox 2 voice prosthesis malfunctioning. J Voice 28(2):250–254
Messing BP, Kim M, Hirata R, Thompson CB, Gebhart S, Sugar EA et al (2015) Evaluation of prophylaxis treatment of Candida in alaryngeal patients with tracheoesophageal voice prostheses. Laryngoscope 125(5):1118–1123
Lorenz KJ, Grieser L, Ehrhart T, Maier H (2010) Role of reflux in tracheoesophageal fistula problems after laryngectomy. Ann Otol Rhinol Laryngol 119(11):719–728
Hutcheson KA, Lewin JS, Sturgis EM, Risser J (2012) Multivariable analysis of risk factors for enlargement of the tracheoesophageal puncture after total laryngectomy. Head Neck 34(4):557–567
Summers L (2017) Social and quality of life impact using a voice prosthesis after laryngectomy [Miscellaneous Article]. Curr Opin Otolaryngol Head Neck Surg 25(3):188–194
Hilgers FJM, Ackerstaff AH, Jacobi I, Balm AJM, Tan IB, van den Brekel MWM (2010) Prospective clinical phase II study of two new indwelling voice prostheses (Provox Vega 22.5 and 20 Fr) and a novel anterograde insertion device (Provox Smart Inserter). Laryngoscope 120(6):1135–1143
Ward EC, Hancock K, Lawson N, van As-Brooks CJ (2011) Perceptual characteristics of tracheoesophageal speech production using the new indwelling Provox Vega voice prosthesis: a randomized controlled crossover trial. Head Neck 33(1):13–19
Serra A, Spinato G, Spinato R, Conti A, Licciardello L, Di Luca M et al (2017) Multicenter prospective crossover study on new prosthetic opportunities in post-laryngectomy voice rehabilitation. J Biol Regul Homeost Agents 31(3):803–809
Lorenz KJ, Maier H (2010) Voice rehabilitation after laryngectomy. Initial clinical experience with the Provox-Vega® voice prosthesis and the SmartInserter® system. HNO 58(12):1174–1183
Funding
There was no funding and none of the authors have received any financial compensation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There was no conflict of interest with the manufacturer of the prostheses.
Human participants
This research involved human participants and was approved by the Hospital’s Ethics Committee.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Mayo-Yáñez, M., Cabo-Varela, I., Dovalo-Carballo, L. et al. Provox 2® and Provox Vega® device life-time: a case-crossover study with multivariate analysis of possible influential factors and duration. Eur Arch Otorhinolaryngol 275, 1827–1830 (2018). https://doi.org/10.1007/s00405-018-5008-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-018-5008-2